Controversial Alzheimer’s drug Aduhelm underwhelmed in early sales. Despite poor performance, some neurologists hope the drug will mean more new Alzheimer’s treatments — and…
In the lead-up to European regulators’ December decision on Aduhelm’s approval for use in the European Union, an expert panel declined to give the…
Medicare premiums are going up in price across the board thanks in part to the anticipated cost of covering Aduhelm — but that doesn’t…
Following the approval of the Alzheimer’s drug Aduhelm — and the litany of controversy surrounding it — one question that’s top of mind for…
The amyloid hypothesis—the idea that Alzheimer’s is caused by clumps of proteins known as beta-amyloid—remains unproven. But scientists are holding out hope that monoclonal…
In our LiveTalk series, Being Patient spoke with Marc Archambault about his early symptoms of Alzheimer’s, the ways in which he has adapted his career…
In Being Patient’s LiveTalk series, retired family physician Dewayne Nash spoke about life after an early diagnosis of Alzheimer’s, his involvement as a subject…